InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol (“CBN”), will be featured at the upcoming VirtualInvestorConferences.com. InMed president and CEO is scheduled to present a real-time, interactive presentations during the two-day conference; InMed’s presentation will start at 1:30 p.m. ET on Sept. 8, 2021. During the presentation Adams will provide an overview of the company’s recent highlights as well as answer questions from potential investors in real time. Company highlights include the announcement that it has increased the yield of its proprietary IntegraSyn(TM) rare cannabinoid manufacturing approach to 5 g/L, further improving the overall economics in advance of commercial-scale production and that it has signed a nonbinding letter of intent to acquire BayMedica, a private company that specializes in the manufacture and commercialization of rare cannabinoids. In addition, as part of a phase 2 clinical trial, InMed has filed clinical trial applications in several countries. Virtual Investor Conferences (“VIC”) has developed a reputation for being a leading proprietary investor conference series; VIC events provide an interactive forum for publicly traded companies to meet and present directly with investors.
To register for the event, visit https://ibn.fm/0HHBZ
To view the full press release, visit https://ibn.fm/GHa2E
About InMed Pharmaceuticals Inc.
InMed is a clinical-stage pharmaceutical company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol (“CBN”) and is developing IntegraSyn to produce pharmaceutical-grade cannabinoids. The company is dedicated to delivering new therapeutic alternatives to patients who may benefit from cannabinoid-based pharmaceutical drugs. For more information, please visit www.InMedPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
